Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in ...

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first ...

Key Points On July 22, 2025, the U.S. Food and Drug Administration issued a Complete Response Letter for RP1, delaying potential commercialization and revenue. Research and development expenses ...

One of the most notable accomplishments of the first Trump Administration was its willingness to take on the status quo of ...

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...

Eli Lilly said this morning that its experimental obesity pill orforglipron fell short of expectations in a late-stage trial, delivering 11.2% weight loss over 72 weeks — less than the 15% to 21% ...

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.